UnitedHealth Group, one of America’s largest health insurers, is facing a storm of challenges—from a criminal investigation to a leadership shake-up—that have rattled markets and erased billions in shareholder value.
CEO exits amid mounting pressure
On May 13, 2025, CEO Andrew Witty stepped down suddenly, citing personal reasons. The board swiftly appointed longtime executive Stephen Hemsley to take over. The abrupt transition followed the company’s decision to withdraw its 2025 financial guidance due to soaring medical costs in its Medicare Advantage business.
DOJ opens Medicare fraud investigation
The Wall Street Journal reported that the U.S. Department of Justice has launched a criminal investigation into UnitedHealth over possible Medicare fraud. Investigators are reportedly focused on whether the company inflated patient risk scores to receive larger payments from the government.
UnitedHealth issued a statement rejecting the report’s accuracy and said it had not been formally notified of any such investigation. “We stand by the integrity of our Medicare Advantage program,” the company said.
Stock collapse deepens
UnitedHealth’s share price has dropped by more than 50% in the past month, wiping out nearly $288 billion in market value. The stock fell 13% on the day the DOJ report broke, its worst weekly decline since 1998.
The sell-off marks a dramatic reversal for one of the Dow Jones Industrial Average’s most reliable performers.
A string of corporate crises
The current turmoil follows a series of damaging events:
- Executive murder: Former UnitedHealthcare CEO Brian Thompson was shot dead in Manhattan in December 2024. The high-profile case remains unresolved and sparked widespread outrage.
- Cyberattack fallout: A major 2024 ransomware attack on Change Healthcare, a UnitedHealth subsidiary, caused weeks of system outages and led to federal investigations.
- Regulatory scrutiny: UnitedHealth is already facing civil and antitrust probes over its data practices and market dominance.
What happens next?
UnitedHealth’s leadership says it is focused on rebuilding investor trust and stabilizing operations. The company aims to reintroduce financial guidance later in 2025, contingent on resolution of the investigation and cost containment in its Medicare segment.
Meanwhile, the DOJ has not confirmed or denied the existence of an active criminal probe.
This content is brought to you by the FingerLakes1.com Team. Support our mission by visiting www.patreon.com/fl1 or learn how you send us your local content here.